The global next generation cancer diagnostics market size accounted for USD 17.74 billion in 2024, grew to USD 19.16 billion in 2025 and is projected to surpass around USD 38.36 billion by 2034, representing a healthy CAGR of 8.02% between 2024 and 2034. The North America next generation cancer diagnostics market size is calculated at USD 7.27 billion in 2024 and is expected to grow at a fastest CAGR of 8.15% during the forecast year.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Next Generation Cancer Diagnostics Market
5.1. COVID-19 Landscape: Next Generation Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Next Generation Cancer Diagnostics Market, By Technology
8.1. Next Generation Cancer Diagnostics Market, by Technology, 2024-2034
8.1.1. Next-generation Sequencing
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Lab-on-a-chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. qPCR & Multiplexing
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Protein Microarrays
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. DNA Microarrays
8.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Next Generation Cancer Diagnostics Market, By Application
9.1. Next Generation Cancer Diagnostics Market, by Application, 2024-2034
9.1.1. Biomarker Development
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Proteomic Analysis
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. CTC Analysis
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Epigenetic Analysis
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Genetic Analysis
9.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Next Generation Cancer Diagnostics Market, By Cancer Type
10.1. Next Generation Cancer Diagnostics Market, by Cancer Type, 2024-2034
10.1.1. Lung Cancer
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Colorectal Cancer
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Breast Cancer
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Cervical Cancer
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Next Generation Cancer Diagnostics Market, By Function
11.1. Next Generation Cancer Diagnostics Market, by Function, 2024-2034
11.1.1. Therapeutic Monitoring
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Prognostics
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Companion Diagnostics
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Cancer Screening
11.1.4.1. Market Revenue and Forecast (2021-2034)
11.1.5. Risk Analysis
11.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 12. Global Next Generation Cancer Diagnostics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Technology (2021-2034)
12.1.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.1.4. Market Revenue and Forecast, by Function (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Technology (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.1.5.4. Market Revenue and Forecast, by Function (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Technology (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.1.6.4. Market Revenue and Forecast, by Function (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Technology (2021-2034)
12.2.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.2.4. Market Revenue and Forecast, by Function (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Technology (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.2.5.4. Market Revenue and Forecast, by Function (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Technology (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.2.6.4. Market Revenue and Forecast, by Function (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Technology (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.2.7.4. Market Revenue and Forecast, by Function (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Technology (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.2.8.4. Market Revenue and Forecast, by Function (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Technology (2021-2034)
12.3.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.3.4. Market Revenue and Forecast, by Function (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Technology (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.3.5.4. Market Revenue and Forecast, by Function (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Technology (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.3.6.4. Market Revenue and Forecast, by Function (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Technology (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.3.7.4. Market Revenue and Forecast, by Function (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Technology (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.3.8.4. Market Revenue and Forecast, by Function (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Technology (2021-2034)
12.4.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.4.4. Market Revenue and Forecast, by Function (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Technology (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.4.5.4. Market Revenue and Forecast, by Function (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Technology (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.4.6.4. Market Revenue and Forecast, by Function (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Technology (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.4.7.4. Market Revenue and Forecast, by Function (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Technology (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.4.8.4. Market Revenue and Forecast, by Function (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Technology (2021-2034)
12.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.5.4. Market Revenue and Forecast, by Function (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Technology (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.5.5.4. Market Revenue and Forecast, by Function (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Technology (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.5.6.4. Market Revenue and Forecast, by Function (2021-2034)
Chapter 13. Company Profiles
13.1. GE HealthCare
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Koninklijke Philips N.V.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Novartis AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Illumina, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. QIAGEN
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Agilent Technologies, Inc. (Dako)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Abbott
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Thermo Fisher Scientific Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Janssen Pharmaceuticals, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample